SEC Form 4 · accession 0001209191-17-042617
ChemoCentryx, Inc. · CCXI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Petrus Bekker
Officer — Chief Medical Officer
Period of report
Jun 28, 2017
Accepted (ET)
Jun 30, 2017 · 7:32 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001340652
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 28, 2017 | M | 30,000 | $7.10 | A | 89,839 | D | |
| Common StockF2 | Jun 28, 2017 | S | 30,000 | $9.1223 | D | 59,839 | D | |
| Common Stock | Jun 29, 2017 | M | 5,509 | $7.10 | A | 65,348 | D | |
| Common StockF2 | Jun 29, 2017 | S | 5,509 | $9.1064 | D | 59,839 | D | |
| Common Stock | Jun 30, 2017 | M | 11,991 | $7.10 | A | 71,830 | D | |
| Common StockF3 | Jun 30, 2017 | S | 11,991 | $9.1224 | D | 59,839 | D | |
| Common Stock | Jun 30, 2017 | M | 18,009 | $6.30 | A | 77,848 | D | |
| Common Stock | Jun 30, 2017 | S | 18,009 | $9.30 | D | 59,839 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F5,F4 | $7.10 | Jun 28, 2017 | M | 30,000 | D | — | Feb 19, 2024 | Common Stock | 30,000 | 160,000 | D |
| Stock Option (right to buy)F5,F4 | $7.10 | Jun 29, 2017 | M | 5,509 | D | — | Feb 19, 2024 | Common Stock | 5,509 | 154,491 | D |
| Stock Option (right to buy)F5,F4 | $7.10 | Jun 30, 2017 | M | 11,991 | D | — | Feb 19, 2024 | Common Stock | 11,991 | 142,500 | D |
| Stock Option (right to buy)F5,F4 | $6.30 | Jun 30, 2017 | M | 18,009 | D | — | Aug 10, 2020 | Common Stock | 18,009 | 29,751 | D |
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
- F2Reflects the weighted average sale price of the shares sold. The shares were sold in multiple trades at prices ranging from $9.10 to $9.16 per share, inclusive. The Reporting Person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.
- F3Reflects the weighted average sale price of the shares sold. The shares were sold in multiple trades at prices ranging from $9.10 to $9.20 per share, inclusive. The Reporting Person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.
- F4As of June 28, 2017, and prior to this transaction, the exercised options were fully vested.
- F5Not applicable.